Division 9 F1
United Kingdom
Boxes 11a, 11b: Enter name of the scheduled substance as stated in the Annex to Regulation (EC) No 111/2005, the commercial name of the medicinal product listed in Category 4, the number of units in the consignment, the number of tablets/ampoules in each unit, the content of the scheduled substance in a single unit (per tablet/ampoule) or in the case of a mixture or natural product enter the name and the 8 digit CN code, as well as the commercial name
Annotations
Textual amendments
- F1
Regulation revoked (N.I.) (29.6.2026) by The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 (S.I. 2026/607), reg. 1(1), Sch.
Notes on Annex IV
Textual amendments
- F2
Annex 4 Form heading: words “UNITED KINGDOM” substituted for “EUROPEAN UNION” (31.12.2020) by The Law Enforcement and Security (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/742), regs. 1, 16(11)(a)(i); 2020 c. 1, Sch. 5 para. 1(1)
- F3
Annex 4 Form box 9: words “United Kingdom” substituted for “customs territory of the Union” (31.12.2020) by The Law Enforcement and Security (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/742), regs. 1, 16(11)(a)(ii); 2020 c. 1, Sch. 5 para. 1(1)
- F4
Annex 4 Form heading: words “European Union or Great Britain” substituted for “UNITED KINGDOM” (29.6.2026) by The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 (S.I. 2026/607), regs. 1(1), 8(8)(a)(i)
- F5
Annex 4 Form box 9: words “Great Britain/the customs territory of the Union” substituted for “the United Kingdom” (29.6.2026) by The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 (S.I. 2026/607), regs. 1(1), 8(8)(a)(ii)